









Markets
/
Stocks
/
nasdaq-ntra
/

Natera Inc

NTRA

192.510USD

-2.490-1.28%

Close 10/24, 16:00（ET）Quotes delayed by 15 min

26.17BMarket Cap

LossP/E TTM



Natera Inc

192.510

-2.490-1.28%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Natera Inc

Currency: USD Updated: 2025-10-23

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Natera Inc's Score

Industry at a Glance

Industry Ranking

3 / 72

Overall Ranking

18 / 4685

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 21 analysts

Buy

Current Rating

194.731

Target Price

+4.20%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Natera Inc Highlights

StrengthsRisks

Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 106.88% year-on-year.

Undervalued

The company’s latest PE is -102.51, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 129.12M shares, decreasing 2.29% quarter-over-quarter.

Held by Stanley Druckenmiller

Star Investor Stanley Druckenmiller holds 3.09M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-23

The company's current financial score is 8.85, which is higher than the Healthcare Providers & Services industry's average of 7.27. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 546.60M, representing a year-over-year increase of 32.24%, while its net profit experienced a year-over-year increase of 169.43%.

Score

Industry at a Glance

Previous score

8.85

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.71

Key Metrics

Free cash flow

No Data

Natera Inc's Company Valuation

Currency: USD Updated: 2025-10-23

The company’s current valuation score is 7.33, which is higher than the Healthcare Providers & Services industry's average of 7.12. Its current P/E ratio is -102.51, which is -94.15% below the recent high of -6.00 and -14.52% above the recent low of -117.39.

Score

Industry at a Glance

Previous score

7.33

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 3/72

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-23

The company’s current earnings forecast score is 8.45, which is higher than the Healthcare Providers & Services industry's average of 7.57. The average price target for Natera Inc is 200.00, with a high of 235.00 and a low of 37.00.

Score

Industry at a Glance

Previous score

8.45

Change

Support & Resistance

No Data

Analyst Rating

Based on 21 analysts

Buy

Current Rating

194.731

Target Price

-0.14%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Natera Inc

NTRA

CVS Health Corp

CVS

HCA Healthcare Inc

HCA

Teladoc Health Inc

TDOC

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-23

The company’s current price momentum score is 9.66, which is higher than the Healthcare Providers & Services industry's average of 7.45. Sideways: Currently, the stock price is trading between the resistance level at 208.61 and the support level at 169.41, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.34

Change

0.32

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MACD(12,26,9)

4.302

Buy

RSI(14)

73.079

Buy

STOCH(KDJ)(9,3,3)

81.893

Buy

ATR(14)

6.511

High Vlolatility

CCI(14)

133.263

Buy

Williams %R

5.541

Overbought

TRIX(12,20)

0.403

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

188.038

Buy

MA10

181.640

Buy

MA20

173.833

Buy

MA50

170.508

Buy

MA100

162.873

Buy

MA200

159.600

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-23

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Providers & Services industry's average of 7.03. The latest institutional shareholding proportion is 94.07%, representing a quarter-over-quarter decrease of 2.65%. The largest institutional shareholder is The Vanguard, holding a total of 12.62M shares, representing 9.20% of shares outstanding, with 0.74% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

12.62M

+2.27%

T. Rowe Price Associates, Inc.

Star Investors

12.07M

+15.72%

JP Morgan Asset Management

8.92M

+39.53%

BlackRock Institutional Trust Company, N.A.

6.78M

+1.51%

Farallon Capital Management, L.L.C.

4.82M

+6.02%

State Street Investment Management (US)

3.32M

-1.57%

Duquesne Family Office LLC

Star Investors

3.09M

-9.32%

Wellington Management Company, LLP

2.63M

-13.92%

RTW Investments L.P.

2.59M

+0.00%

Geode Capital Management, L.L.C.

2.55M

+6.99%

Risk Assessment

Currency: USD Updated: 2025-10-23

The company’s current risk assessment score is 7.39, which is higher than the Healthcare Providers & Services industry's average of 5.58. The company's beta value is 1.72. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.